CD9 AML-M3 ve HLA-DR-Negatif M3 Dışı AML’nin Ayırt Edilmesinde Çok Yararlı Bir Belirteçtir

Kaynakça (7)

1. Touzet L, Dumezy F, Roumier C, Berthon C, Bories C, Quesnel B, Preudhomme C, Boyer T. CD9 in acute myeloid leukemia: prognostic role and usefulness to target leukemic stem cells. Cancer Med 2019;8:1279-1288
2. Allahbakhshian M, Shahabi Satlsar E, Mohseni A, Mosleh M, Mehrpouri M, Agaeipour M, Mohammadi MH, Gholampour R, Jadali F. Use of four-color flow cytometric assay for discrimination of hematogone from lymphoblast: critical issue for MRD assessment in B-ALL patients. Iran J Ped Hematol Oncol 2020;10:17-27
3. Yamazaki H, Xu CW, Naito M, Nishida H, Okamoto T, Ghani FI, Iwata S, Inukai T, Sugita K, Morimoto C. Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia. Biochem Biophys Res Commun 2011;409:14-21
4. Adams J, Nassiri M. Acute promyelocytic leukemia: a review and discussion of variant translocations. Arch Pathol Lab Med 2014;139:1308-1313
5. Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR. HLA-DR antigen-negative acute myeloid leukemia. Leukemia 2003;17:707-715
6. Mosleh M, Mehrpouri M, Ghaffari S, Saei Z, Agaeipoor M, Jadali F, Satlsar ES, Gholampour R. Report of a new six-panel flow cytometry marker for early differential diagnosis of APL from HLADR negative non-APL leukemia. Scand J Clin Lab Invest 2020;80:87-92
7. Akhtar K, Ahmad S, Shervani RK. Acute promyelocytic leukemia, hypogranular variant: a rare presentation. Clin Pract 2011;1:e11.